Previous close | 70.81 |
Open | 70.81 |
Bid | 69.29 x 800 |
Ask | 71.33 x 800 |
Day's range | 70.03 - 71.32 |
52-week range | 65.07 - 86.29 |
Volume | |
Avg. volume | 1,687,611 |
Market cap | 15.677B |
Beta (5Y monthly) | 0.74 |
PE ratio (TTM) | 47.19 |
EPS (TTM) | 1.49 |
Earnings date | 01 May 2023 - 05 May 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 89.25 |
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
WILMINGTON, Del. & TOKYO, March 27, 2023--Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)